NUCLEOTIDE CYCLIC CLEAVABLE MOIETIES AND USES THEREOF

1 . (canceled)

2 . A compound having the formula:

wherein,

Ring A is an unsubstituted heterocycloalkyl comprising two adjacent sulfur atoms, unsubstituted heteroaryl comprising two adjacent sulfur atoms, a substituted heterocycloalkyl comprising two adjacent sulfur atoms, or a substituted heteroaryl comprising two adjacent sulfur atoms;

B 2 is a divalent nucleobase;

R 1 is a polyphosphate moiety, monophosphate moiety, 5′-nucleoside protecting group, or —OH;

R 2 is hydrogen, halogen, —CCl 3 , —CBr 3 , —CF 3 , —CI 3 , —CHCl 2 , —CHBr 2 , —CHF 2 , —CHI 2 , —CH 3 Cl, —CH 2 Br, —CH 2 F, —CH 2 I, —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl 3 , —OCF 3 , —OCBr 3 , —OCI 3 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , —OCHF 2 , —OCH 3 Cl, —OCH 2 Br, —OCH 2 I, —OCH 2 F, —N 3 , —SF 5 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a polymerase-compatible cleavable moiety;

R 4 is a detectable moiety; and

L 100 is a divalent linker.

3 . The compound of claim 2 , wherein Ring A is

R 13A is independently substituted or unsubstituted alkyl, oxo, halogen, —CCl 3 , —CBr 3 , —CF 3 , —CI 3 , —CHCl 2 , —CHBr 2 , —CHF 2 , —CHI 2 , —CH 2 Cl, —CH 2 Br, —CH 2 F, —CH 2 I, —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl 3 , —OCF 3 , —OCBr 3 , —OCI 3 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , —OCHF 2 , —OCH 2 Cl, —OCH 2 Br, —OCH 2 I, —OCH 2 F, —N 3 , —SF 5 , —SiH 3 , —Si(R 13C ) 3 , substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; two adjacent R 13A substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 13C is independently unsubstituted C 1 -C 8 alkyl; and

z10 is an integer from 0 to 11.

4 . The compound of claim 2 , wherein Ring A is

wherein m is an integer from 0 to 8.

5 . The compound of claim 2 , wherein Ring A is

6 . The compound of claim 2 , wherein Ring A is

wherein z10 is an integer from 0 to 6.

7 . The compound of claim 2 , wherein Ring A is

wherein z10 is an integer from 0 to 6.

8 . The compound of claim 2 , wherein Ring A is

9 . The compound of claim 2 , wherein Ring A is

10 . The compound of claim 2 , wherein Ring A is

11 .- 15 . (canceled)

12 . The compound of claim 2 , wherein

B 2 is a divalent cytosine or a derivative thereof, divalent guanine or a derivative thereof, divalent adenine or a derivative thereof, divalent thymine or a derivative thereof, divalent uracil or a derivative thereof, divalent hypoxanthine or a derivative thereof, divalent xanthine or a derivative thereof, divalent 7-methylguanine or a derivative thereof, divalent 5,6-dihydrouracil or a derivative thereof, divalent 5-methylcytosine or a derivative thereof, or divalent 5-hydroxymethylcytosine or a derivative thereof.

17 .- 19 . (canceled)

13 . The compound of claim 2 , wherein L 100 is a divalent linker comprising:

14 . The compound of claim 2 , wherein L 100 is a divalent linker comprising:

15 . The compound of claim 2 , wherein L 100 is a divalent linker comprising:

16 . The compound of claim 2 , wherein L 100 is a divalent linker comprising

17 . The compound of claim 2 , having the formula

18 . The compound of claim 24 , wherein L 100 is

L 100 , L 103 , L 104 , and L 105 are independently a bond, —NH—, —O—, —C(O)—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;

R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

R 102 is unsubstituted C 1 -C 4 alkyl.

19 . (canceled)

20 . The compound of claim 24 , wherein L 100 is

wherein L 101 , L 103 , L 104 , and L 105 are independently a bond, —NH—, —O—, —C(O)—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and

Ring A is an unsubstituted heterocycloalkylene, unsubstituted heteroarylene, a substituted heterocycloalkylene, or a substituted heteroarylene.

21 . The compound of claim 24 , wherein L 100 is

wherein L 103 , L 104 , and L 105 are independently a bond, —NH—, —O—, —C(O)—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

22 .- 35 . (canceled)

23 . A method of detecting a nucleic acid molecule, said method comprising:

contacting a primer hybridized to the nucleic acid molecule with a compound of claim 2 , wherein said nucleic acid molecule is in a cell or tissue;

incorporating with a polymerase said compound into the primer; and

detecting the detectable moiety, thereby detecting the nucleic acid molecule.

24 .- 38 . (canceled)

25 . The method of claim 36 , further comprising contacting the primer with an unlabeled nucleotide.

26 .- 55 . (canceled)